Toray Develops Porous Fiber Technology to Adsorb Pathogenic Substances in Intractable Diseases
Toray Industries has developed a technology to precisely control the pore size of PMMA porous fibers up to approximately 1,000nm. This breakthrough enables the selective removal of large-molecular-weight pathogenic substances, offering a new approach for blood purification treatments. The company aims to commercialize this for treating intractable diseases and biopharmaceutical manufacturing.
📋 Article Processing Timeline
- 📰 Published: March 27, 2026 at 00:05
- 🔍 Collected: March 28, 2026 at 21:59 (45h 54m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 03:36 (413h 36m after Collected)
Toray Industries, Inc. announced the development of a technology that allows for the arbitrary control of pore sizes in polymethyl methacrylate (PMMA) porous fibers, ranging from several nm to approximately 1,000nm. This technology enables the selective adsorption of pathogenic substances that were previously difficult to remove, contributing to new blood purification treatment options for autoimmune diseases, cardiovascular metabolic disorders, neurodegenerative diseases, and cancer. Leveraging its expertise in PMMA, which has a 50-year track record in blood purification, Toray plans to advance the design and mass production of these fibers for various clinical applications and biopharmaceutical production.
FAQ
Which diseases could this technology help treat?
It is expected to contribute to blood purification treatments for intractable diseases such as autoimmune diseases, cardiovascular metabolic disorders, neurodegenerative diseases, and cancer.
How does this technology differ from conventional fibers?
It allows for pore size control up to approximately 1,000nm—more than 50 times larger than before—enabling the selective removal of large-molecular-weight pathogenic substances.